TAXOTERE® RECEIVES POSITIVE OPINION
TAXOTERE® RECEIVES POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE RECOMMENDING APPROVAL IN THE EUROPEAN UNION FOR METASTATIC STOMACH CANCER
Ämnen: Vetenskap, teknik
-
-
TAXOTERE® RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER
TAXOTERE®-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
-
New therapy significantly reduces risk of repeat heart attack and death
Brigham and Womens Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning Strategy For Heart Attacks - New therapy significantly reduces risk of repeat heart attack and death
-
FIRST LARGE SCALE INTERNATIONAL PRIMARY CARE STUDY CONFIRMS A HIGH WAIST CIRCUMFERENCE IS INDEPENDENTLY ASSOCIATED WITH CARDIOVASCULAR DISEASE
Results from the IDEA Study Highlight the Rising Worldwide Pandemic of Abdominal Obesity
-
Varannan svensk vill minska sin midja
Om svensken själv får välja är det den tjocka magen som ska bort. 51 procent av svenskarna vill ha smalare midja. En majoritet anger omsorg om hälsan som skäl, inte utseende. Det visar en färsk undersökning från Temo.
-
STUDY ANALYZES GENE THERAPY FOR PATIENTS AT HIGH RISK FOR AMPUTATION
NV1FGF Injection Reduces and Delays Risks of Amputation in Patients with Limb Ischemia
-
CHARISMA: NEW STUDY FURTHERS UNDERSTANDING OF THE ROLE OF DUAL ANTIPLATELET THERAPY IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS
Results from the CHARISMA trial showed that the combination of the antiplatelet agents clopidogrel and aspirin did not demonstrate a statistically significant reduction in the risk of heart attack, stroke or cardiovascular death compared to placebo and aspirin in a broad population of patients with either established atherothrombotic disease or multiple risk factors for atherothrombotic events.
-
Apidra ® A New Rapid-Acting Insulin Analog is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
New prandial insulin with the OptiClik® delivery system can work with longer-acting insulins, such as basal insulin Lantus®, providing a complementary approach to glucose control
-
SANOFI PASTEUR DELIVERS MORE H5N1 VACCINE FOR U.S. GOVERNMENT PANDEMIC INITIATIVES
Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.
-
Svenska Cardiologföreningen och sanofi-aventis stödjer forskning rörande prevention av hjärtkärlsjukdomar med utgångspunkt från kända kardiovaskulära och metabola riskfaktorer.
Svenska Cardiologföreningen och sanofi-aventis utlyser ett stipendium om 150 000 kronor inom området kardiometabol risk.
-
MY CHILD MATTERS: LAUNCH OF A MOBILISATION CAMPAIGN AGAINST CHILDHOOD CANCER IN EMERGING COUNTRIES
The International Union against Cancer (UICC) and sanofi-aventis are launching a mobilisation program against childhood cancer in emerging countries, in preparation for World Cancer Day, February 4, 2006.
-
PLAVIX® APPROVED IN JAPAN
Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder.
-
FDA GRANTS PRIORITY REVIEW TO PLAVIXÒ (clopidogrel bisulfate) SUPPLEMENTAL NEW DRUG APPLICATION (sNDA) FOR ADDITIONAL TYPE OF HEART ATTACK
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) for treatment of patients with acute STsegment elevation myocardial infarction (STEMI).
-
SANOFI PASTEUR ANNOUNCES PRELIMINARY TRIAL RESULTS FOR A FIRST H5N1 PRE-PANDEMIC INFLUENZA VACCINE CANDIDATE WITH AN ADJUVANT
Vice President Communications sanofi pasteur: Alain BERNAL U. S. Media Relations: Len LAVENDA Tel.: +1 570 839 7187 - Fax: +1 570 839 0955 - Sanofi Pasteur Inc. - Discovery Drive - Swiftwater, PA 18370-0187 - USA - www.sanofipasteur.com ~ Data Show that the Vaccine Is Safe, Demonstrates Immunogenicity and Provides Future Direction For Development ~ Lyon, France December 15, 2005 Sano
-
INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE®-BASED REGIMENS WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN WOMEN WITH EARLY-STAGE HER2-POSITIVE BREAST CANCER
Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen (TCH) with TAXOTERE® (docetaxel), the platinum salt carboplatin and HERCEPTIN® (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer Paris and San Antonio December 8th, 2005 The Breast Cancer International Research Group
-
NEW ENGLAND JOURNAL OF MEDICINE PUBLICERAR RIO-LIPIDS-STUDIEN
Studie visar att rimonabant signifikant reducerar kardiovaskulära och metabola riskfaktorer hos överviktiga och feta patienter Paris, Frankrike, 16 november 2005 Sanofi-aventis tillkännagav att resultaten från RIO-Lipidsstudien publicerades i dag i The New England Journal of Medicine. I studien undersöktes effekten av rimonabant hos patienter med övervikt och fetma samt avvikande blodfetter (
-
INTERNATIONELL DIABETESUNDERSÖKNING BELYSER ATT PERSONER MED DIABETES OCH VÅRDGIVARE HAR OLIKA UPPFATTNINGAR OM SJUKDOMEN OCH HUR DEN SKA BEHANDLAS
En stor undersökning som publiceras på World Diabetes Day 14 november 2005 visar att diabetiker i större utsträckning vill medverka vid beslut som rör behandlingen av sjukdomen. Paris, 14 november 2005 Resultaten av en undersökning som publiceras idag på World Diabetes Day visar att nästan 80% av allmänheten personligen känner någon som har diabetes. För närvarande finns fler än 194 miljon
-
SANOFI PASTEUR SIGNS CONTRACT WITH FRENCH GOVERNMENT TO PRODUCE PANDEMIC INFLUENZA VACCINE
Alain BERNAL Vice-President Corporate Communications Tel: + 33-(0)4-37-37-78-97 Fax: +33-(0)4-37-37-77 89 Len LAVENDA U.S. Media Relations Tel: +1-570-839-4446 Len.Lavenda@sanofipasteur.com ~ Influenza Vaccine Leader sanofi Pasteur Contributes to French Pandemic Preparedness ~ Lyon, France November 10, 2005 Following discussions which started a few months ago, sanofi pasteur,
-
TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR
MICROBIOLOGICAL ACTIVITY OF TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR TO OTHER STANDARD FIRST LINE ANTIBIOTICS OVER 4-YEAR PERIOD New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible Paris, 20 September 2005 Data presented today at the 15th Annual Internati
-
TAXOTERE®-BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER Interim analysis of more than 3,000 patients in BCIRG006 study also shows TAXOTERE® non-anthracycline-based chemotherapy combined with HERCEPTIN® improved disease-free surviv
Visa mer
Loading...